Anika Therapeutics’ (ANIK) “Buy” Rating Reiterated at B. Riley Financial

Anika Therapeutics (NASDAQ:ANIK – Get Free Report)‘s stock had its “buy” rating restated by B. Riley Financial in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $17.00 price target on the biotechnology company’s stock, down from their previous price target of $23.00. B. Riley Financial‘s price target indicates a potential upside of 26.87% from the stock’s current price.

A number of other research firms also recently weighed in on ANIK. Barrington Research set a $21.00 price target on shares of Anika Therapeutics in a research note on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Anika Therapeutics in a research report on Monday, September 21st. Wall Street Zen raised shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Finally, Zacks Research cut shares of Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Anika Therapeutics has an average rating of “Hold” and an average price target of $19.00.

Read Our Latest Stock Report on Anika Therapeutics

Anika Therapeutics Price Performance

Shares of Anika Therapeutics stock opened at $13.40 on Monday. The company has a market capitalization of $179.56 million, a price-to-earnings ratio of -103.07, a PEG ratio of 9.57 and a beta of 0.21. Anika Therapeutics has a 12-month low of $9.01 and a 12-month high of $22.88. The firm’s 50-day moving average price is $19.66 and its two-hundred day moving average price is $16.36.

Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last released its earnings results on Friday, November 6th. The biotechnology company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.13). Anika Therapeutics had a negative net margin of 1.43% and a positive return on equity of 1.87%. The firm had revenue of $30.59 million during the quarter, compared to the consensus estimate of $29.44 million. On average, sell-side analysts expect that Anika Therapeutics will post 0.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ANIK. BlackRock Inc. bought a new stake in shares of Anika Therapeutics during the 2nd quarter valued at about $21,209,000. Deutsche Bank AG bought a new stake in Anika Therapeutics in the second quarter worth approximately $5,172,000. Man Group plc bought a new stake in Anika Therapeutics in the second quarter worth approximately $2,059,000. Quantinno Capital Management LP increased its holdings in Anika Therapeutics by 23.9% in the first quarter. Quantinno Capital Management LP now owns 125,826 shares of the biotechnology company’s stock worth $1,824,000 after purchasing an additional 24,277 shares in the last quarter. Finally, Globeflex Capital L P acquired a new position in Anika Therapeutics in the second quarter valued at approximately $1,282,000. 91.53% of the stock is owned by institutional investors.

About Anika Therapeutics

(Get Free Report)

Anika Therapeutics is a medical technology company focused on orthopedic care and regenerative medicine. Founded in 1992 and headquartered in Bedford, Massachusetts, the company develops products using hyaluronic acid, a substance found naturally in the body and used in treatments for joint and tissue conditions. Its products include Orthovisc and Monovisc, injectable hyaluronic acid treatments for knee osteoarthritis. Anika also offers orthopedic products for areas such as sports medicine, joint preservation, and bone repair, including its Tactoset bone-void filler.

Further Reading

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.